Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus UNASYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus UNASYN.
AMPICILLIN SODIUM vs UNASYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic